Cosmo Pharmaceuticals NV
SIX:COPN
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
38.9
79.9
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CHF.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Cosmo Pharmaceuticals NV
Cosmo Pharmaceuticals NV
Accounts Payable
Cosmo Pharmaceuticals NV
Accounts Payable Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Accounts Payable | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Cosmo Pharmaceuticals NV
SIX:COPN
|
Accounts Payable
€14.7m
|
CAGR 3-Years
14%
|
CAGR 5-Years
13%
|
CAGR 10-Years
8%
|
|
|
Perrigo Company PLC
NYSE:PRGO
|
Accounts Payable
$458.5m
|
CAGR 3-Years
4%
|
CAGR 5-Years
-3%
|
CAGR 10-Years
4%
|
|
|
Jazz Pharmaceuticals PLC
NASDAQ:JAZZ
|
Accounts Payable
$85.4m
|
CAGR 3-Years
10%
|
CAGR 5-Years
4%
|
CAGR 10-Years
11%
|
|
|
Avadel Pharmaceuticals PLC
NASDAQ:AVDL
|
Accounts Payable
$7.9m
|
CAGR 3-Years
5%
|
CAGR 5-Years
17%
|
CAGR 10-Years
1%
|
|
|
G
|
GH Research PLC
NASDAQ:GHRS
|
Accounts Payable
$3.5m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Ovoca Bio PLC
LSE:OVB
|
Accounts Payable
€451k
|
CAGR 3-Years
-29%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
2%
|
|
Cosmo Pharmaceuticals NV
Glance View
Cosmo Pharmaceuticals NV engages in the development, manufacturing, and distribution of treatments for gastrointestinal diseases, endoscopy, colorectal cancer diagnosis, and colonoscopy. The company is headquartered in Dublin, Dublin and currently employs 290 full-time employees. The company went IPO on 2016-05-18. The firm develops therapies for gastrointestinal disorders. The firm's clinical development pipeline specifically addresses treatments for inflammatory bowel diseases, colorectal cancer diagnosis and colonoscopy. The company has developed a medical device for polyp excision and is developing a product for the detection of colon cancer. Its pipeline includes Lialda/Mezavant/Mesavancol, which is indicated for mild to moderate ulcerative colitis; Uceris/Cortiment, which is indicated for mild to moderate ulcerative colitis; Zacol NMX, which is indicated for intestinal disorders; Rifamycin SV MMX, which is indicated for Travelers' Diarrhea and uncomplicated diverticulitis, among others; CB-17-01, which is indicated for chromoendoscopy for colorectal cancer prevention in surveillance patients; CB-17-04, which is a sub mucosal injectable composition, and CB-01-12, which is an antibody anti-tumor necrosis factor (TNF) alpha drug.
See Also
What is Cosmo Pharmaceuticals NV's Accounts Payable?
Accounts Payable
14.7m
EUR
Based on the financial report for Jun 30, 2024, Cosmo Pharmaceuticals NV's Accounts Payable amounts to 14.7m EUR.
What is Cosmo Pharmaceuticals NV's Accounts Payable growth rate?
Accounts Payable CAGR 10Y
8%
Over the last year, the Accounts Payable growth was 34%. The average annual Accounts Payable growth rates for Cosmo Pharmaceuticals NV have been 14% over the past three years , 13% over the past five years , and 8% over the past ten years .
You don't have any saved screeners yet
